Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
OPINION article Front. Mol. Neurosci., 17 May 2019Sec. Brain Disease Mechanisms Volume 12 - 2019 | https://doi.org/10.3389/fnmol.2019.00123
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Dopamine in motivational control: rewarding, aversive, and alerting
Bromberg-Martin, E. S., Matsumoto, M., & Hikosaka, O. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.022 · Cited by 2,396 · cited 1×
“From a clinical point of view, the VTA degeneration in AD could be particularly relevant for the manifestation of neuropsychiatric symptoms since mesocorticolimbic dopamine broadly regulates non-motor behavior like motivation, reward, pleasure, attention, emotional processing, and mood conditioning [Figure 1B; (Grace…”
BackgroundLyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049 · cited 2×
“…models, emphasizing the critical role of dopamine for proper brain function (Monteverde et al., 1990; Tsunekawa et al., 2008; Himeno et al., 2011; Jürgensen et al., 2011; Koch et al., 2011, 2014; Guzmán-Ramos et al., 2012; Pazini et al., 2013; Martorana and Koch, 2014; Nobili et al., 2017).”
BackgroundThe brain reward circuitry in mood disorders
Russo, S. J., & Nestler, E. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3381 · Cited by 1,870 · cited 1×
“From a clinical point of view, the VTA degeneration in AD could be particularly relevant for the manifestation of neuropsychiatric symptoms since mesocorticolimbic dopamine broadly regulates non-motor behavior like motivation, reward, pleasure, attention, emotional processing, and mood conditioning [Figure 1B; (Grace…”
BackgroundTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848 · cited 1×
“…of dopamine, mitochondrial dysfunction, oxidative stress, impaired protein degradation, metal homeostasis, neurochemistry of metalloproteins and neuroinflammation (Schapira, 2001; Liss et al., 2005; Surmeier, 2007; Lim et al., 2016; Burbulla et al., 2017; Mor et al., 2017; Adlard and Bush, 2018).”
BackgroundDopamine neuron systems in the brain: An update
Björklund, A., & Dunnett, S. B. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.006 · Cited by 1,777
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Regulation of firing of dopaminergic neurons and control of goal-directed behaviors
Grace, A. A., Floresco, S. B., Goto, Y., & Lodge, D. J. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.003 · Cited by 1,034
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017 · cited 7×
“Direct comparison of patients with and without neuropsychiatric symptoms confirmed that patients with apathy, depression or anxiety have more severe functional disconnection between the VTA and the default-mode network compared to patients that lacked such symptoms (Serra et al., 2018).”
BackgroundMethodInfluentialUnique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system
Lammel, S., Hetzel, A., Häckel, O., Jones, I., Liss, B., & Roeper, J. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.022 · Cited by 976
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Locus coeruleus and dopaminergic consolidation of everyday memory
Takeuchi, T., Duszkiewicz, A. J., Sonneborn, A., Spooner, P. A., Yamasaki, M., Watanabe, M., Smith, C. C., Fernández, G., Deisseroth, K., Greene, R. W., et al. (2016) · Nature · doi:10.1038/nature19325 · Cited by 827
Ismail, Z., Smith, E. E., Geda, Y., Sultzer, D., Brodaty, H., Smith, G., Agüera‐Ortiz, L., Sweet, R., Miller, D., Lyketsos, C. G., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.017 · Cited by 818
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“…these data suggest that Aβ deposition might be a phenomenon of aging or a consequence of an upstream event and not the causative reason for AD, with scientists now questioning the validity of the amyloid hypothesis (Hardy and Selkoe, 2002; Tanzi and Bertram, 2005; Chételat, 2013; Herrup, 2015).”
BackgroundNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 1×
“Conversely, active social engagement, physical exercise, balanced diet, and mentally-stimulating activity have been suggested as beneficial for delaying the clinical manifestation of AD (Kivipelto et al., 2001; Qiu et al., 2009; Mayeux and Stern, 2012; Knight et al., 2014; Winblad et al., 2016).”
BackgroundKempadoo, K. A., Mosharov, E. V., Choi, S. J., Sulzer, D., & Kandel, E. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616515114 · Cited by 647
Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518
Alzheimer neuropathologic alterations in aged cognitively normal subjects
Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199904000-00008 · Cited by 516 · cited 1×
“…AD patients can show low Aβ plaque load (Edison et al., 2007; Li et al., 2008), while in the brain of elderly nondemented patients the distribution of Aβ plaques can be as extensive as that of dementia patients (Davis et al., 1999; Fagan et al., 2009; Price et al., 2009; Chételat et al., 2013).”
BackgroundNobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514
Self-citationCircadian rest-activity pattern changes in aging and preclinical Alzheimer disease
Musiek, E. S., Bhimasani, M., Zangrilli, M. A., Morris, J. C., Holtzman, D. M., & Ju, Y.-E. S. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4719 · Cited by 465
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling
Poulin, J.-F., Zou, J., Drouin-Ouellet, J., Kim, K.-Y. A., Cicchetti, F., & Awatramani, R. B. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.008 · Cited by 352 · cited 1×
“…that differentiate them from each other, such as different potassium and calcium conductances, calcium-binding proteins, or genetic profiling (Neuhoff et al., 2002; Liss et al., 2005; Lammel et al., 2008; Guzman et al., 2009; Khaliq and Bean, 2010; Panman et al., 2014; Poulin et al., 2014).”
BackgroundBapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304 · cited 1×
“Nonetheless, attempts to clear Aβ from the brain led to failure of several long and promising clinical trials (Doody et al., 2013; Cummings et al., 2014; Gauthier et al., 2016; Vandenberghe et al., 2016; Anderson et al., 2017; Carroll, 2017; Coleman and Mastroeni, 2017; Honig et al., 2018).”
BackgroundLocus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0411-2 · Cited by 286
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285
Khaliq, Z. M., & Bean, B. P. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0143-10.2010 · Cited by 261
Why has therapy development for dementia failed in the last two decades?
Gauthier, S., Albert, M., Fox, N., Goedert, M., Kivipelto, M., Mestre‐Ferrandiz, J., & Middleton, L. T. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.003 · Cited by 238
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236
Knight, E. M., Martins, I. V. A., Gümüsgöz, S., Allan, S. M., & Lawrence, C. B. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.010 · Cited by 232 · cited 1×
“Conversely, active social engagement, physical exercise, balanced diet, and mentally-stimulating activity have been suggested as beneficial for delaying the clinical manifestation of AD (Kivipelto et al., 2001; Qiu et al., 2009; Mayeux and Stern, 2012; Knight et al., 2014; Winblad et al., 2016).”
BackgroundWhy do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228
Liu, Y., Yoo, M.-J., Savonenko, A., Stirling, W., Price, D. L., Borchelt, D. R., Mamounas, L., Lyons, W. E., Blue, M. E., & Lee, M. K. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4218-08.2008 · Cited by 206 · cited 3×
“Additionally, population studies show that circadian rhythm disturbances and the frequency of mood symptoms are much higher in people with AD or MCI compared to the general population (Lyketsos et al., 2002, 2011; Taragano et al., 2009).”
BackgroundPanman, L., Papathanou, M., Laguna, A., Oosterveen, T., Volakakis, N., Acampora, D., Kurtsdotter, I., Yoshitake, T., Kehr, J., Joodmardi, E., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.016 · Cited by 143 · cited 1×
“…models, emphasizing the critical role of dopamine for proper brain function (Monteverde et al., 1990; Tsunekawa et al., 2008; Himeno et al., 2011; Jürgensen et al., 2011; Koch et al., 2011, 2014; Guzmán-Ramos et al., 2012; Pazini et al., 2013; Martorana and Koch, 2014; Nobili et al., 2017).”
BackgroundGuzmán-Ramos, K., Moreno-Castilla, P., Castro-Cruz, M., McGaugh, J. L., Martínez-Coria, H., LaFerla, F. M., & Bermúdez-Rattoni, F. (2012) · Learning & Memory · doi:10.1101/lm.026070.112 · Cited by 127
In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer’s disease
Serra, L., D'Amelio, M., Di Domenico, C., Dipasquale, O., Marra, C., Mercuri, N. B., Caltagirone, C., Cercignani, M., & Bozzali, M. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.012 · Cited by 91 · cited 1×
“All these factors have been extensively studied in PD to explain the loss of SNpc neurons [reviewed in (Sulzer, 2007; Surmeier et al., 2011; Tambasco et al., 2018)] but their contribution to the vulnerability of VTA or LC dopamine neurons is yet to be defined.”
BackgroundSelf-citationJürgensen, S., Antonio, L. L., Mussi, G. E. A., Brito-Moreira, J., Bomfim, T. R., De Felice, F. G., Garrido-Sanabria, E. R., Cavalheiro, É. A., & Ferreira, S. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.177790 · Cited by 88
Moreno-Castilla, P., Rodriguez-Duran, L. F., Guzman-Ramos, K., Barcenas-Femat, A., Escobar, M. L., & Bermudez-Rattoni, F. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.021 · Cited by 84 · cited 2×
“…(Noebels, 2011; Pandis and Scarmeas, 2012), neuropsychiatric symptoms, mainly apathy, depression, aggression, and circadian rhythm disturbances (Lyketsos et al., 2011; Masters et al., 2015; Alves et al., 2017; Musiek et al., 2018), impose an additional burden on patients and their families.”
BackgroundCordella, A., Krashia, P., Nobili, A., Pignataro, A., La Barbera, L., Viscomi, M. T., Valzania, A., Keller, F., Ammassari-Teule, M., Mercuri, N. B., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.006 · Cited by 82
Krashia, P., Martini, A., Nobili, A., Aversa, D., D'Amelio, M., Berretta, N., Guatteo, E., & Mercuri, N. B. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13364 · Cited by 61
Self-citation
Cited by
Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry
Fanet, H., Capuron, L., Castanon, N., Calon, F., & Vancassel, S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666200729103529 · Cited by 134
La Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E. C., Cutuli, D., Cauzzi, E., Marino, R., Viscomi, M. T., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102031 · Cited by 98
Self-citationRouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
“This study suggests that this sonogenetics approach has a therapeutic perspective in other neurodegenerative diseases especially AD due to the changes in the dopaminergic system reported in AD patients with cognitive symptoms [136,137].”
Background
Metadata
- Authors
- Krashia, P., Nobili, A., & D'Amelio, M.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-05-17
- Volume
- 12
- Pages
- 123-123
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2946450511
- Cited by
- 71
- References
- 46
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.